Dr. Jean M. Tersak

Claim this profile

Children's Hospital of Pittsburgh of UPMC

Expert in Tumors
Expert in Neuroblastoma
42 reported clinical trials
98 drugs studied

Area of expertise

1Tumors
Global Leader
Jean M. Tersak has run 19 trials for Tumors. Some of their research focus areas include:
Stage I
Stage IV
Stage II
2Neuroblastoma
Global Leader
Jean M. Tersak has run 18 trials for Neuroblastoma. Some of their research focus areas include:
MYC positive
Stage IV
MYC negative

Affiliated Hospitals

Image of trial facility.
Children's Hospital Of Pittsburgh Of UPMC
Image of trial facility.
Children's Hospital Of Pittsburgh

Clinical Trials Jean M. Tersak is currently running

Image of trial facility.

Genetic Testing-Directed Therapy

for Pediatric Cancer

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria

More about Jean M. Tersak

Clinical Trial Related7 years of experience running clinical trials · Led 42 trials as a Principal Investigator · 15 Active Clinical Trials
Treatments Jean M. Tersak has experience with
  • Cyclophosphamide
  • Etoposide
  • Cytology Specimen Collection Procedure
  • Laboratory Biomarker Analysis
  • Carboplatin
  • Doxorubicin Hydrochloride

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jean M. Tersak specialize in?
Jean M. Tersak focuses on Tumors and Neuroblastoma. In particular, much of their work with Tumors has involved Stage I patients, or patients who are Stage IV.
Is Jean M. Tersak currently recruiting for clinical trials?
Yes, Jean M. Tersak is currently recruiting for 9 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Jean M. Tersak has studied deeply?
Yes, Jean M. Tersak has studied treatments such as Cyclophosphamide, Etoposide, Cytology Specimen Collection Procedure.
What is the best way to schedule an appointment with Jean M. Tersak?
Apply for one of the trials that Jean M. Tersak is conducting.
What is the office address of Jean M. Tersak?
The office of Jean M. Tersak is located at: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania 15224 United States. This is the address for their practice at the Children's Hospital of Pittsburgh of UPMC.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.